Weaver C. Barksdale & Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.49M | Sell |
9,898
-11
| -0.1% | -$2.37K | 2.23% | 5 |
|
|
2026
Q1 | $2.15M | Buy |
9,909
+610
| +7% | +$135K | 2.05% | 8 |
|
|
2025
Q4 | $2.12M | Sell |
9,299
-1,132
| -11% | -$258K | 2.23% | 6 |
|
|
2025
Q3 | $2.41M | Sell |
10,431
-648
| -6% | -$132K | 2.32% | 5 |
|
|
2025
Q2 | $2.06M | Sell |
11,079
-101
| -0.9% | -$18.8K | 1.97% | 14 |
|
|
2025
Q1 | $2.34M | Sell |
11,180
-256
| -2% | -$49.8K | 2.25% | 5 |
|
|
2024
Q4 | $2.03M | Sell |
11,436
-276
| -2% | -$50.7K | 1.95% | 18 |
|
|
2024
Q3 | $2.31M | Sell |
11,712
-431
| -4% | -$80.4K | 2.08% | 13 |
|
|
2024
Q2 | $2.08M | Sell |
12,143
-189
| -2% | -$31.3K | 1.98% | 14 |
|
|
2024
Q1 | $2.24M | Sell |
12,332
-97
| -0.8% | -$16.7K | 2.06% | 13 |
|
|
2023
Q4 | $1.93M | Sell |
12,429
-3,121
| -20% | -$455K | 1.88% | 18 |
|
|
2023
Q3 | $2.32M | Buy |
15,550
+2,588
| +20% | +$380K | 1.98% | 17 |
|
|
2023
Q2 | $1.75M | Sell |
12,962
-787
| -6% | -$115K | 1.73% | 29 |
|
|
2023
Q1 | $2.19M | Sell |
13,749
-668
| -5% | -$102K | 2.05% | 7 |
|
|
2022
Q4 | $2.33M | Buy |
14,417
+363
| +3% | +$55.7K | 2.05% | 8 |
|
|
2022
Q3 | $1.89M | Sell |
14,054
-498
| -3% | -$71.5K | 1.89% | 12 |
|
|
2022
Q2 | $2.23M | Sell |
14,552
-3,457
| -19% | -$528K | 2.08% | 3 |
|
|
2022
Q1 | $2.92M | Buy |
18,009
+249
| +1% | +$36.2K | 2.6% | 1 |
|
|
2021
Q4 | $2.4M | Buy |
+17,760
| New | +$2.1M | 2.18% | 2 |
|
|
2017
Q4 | $2.07M | Sell |
21,414
-694
| -3% | -$65.4K | 2.18% | 1 |
|
|
2017
Q3 | $1.97M | Hold |
22,108
| – | – | 2.19% | 1 |
|
|
2017
Q2 | $1.6M | Hold |
22,108
| – | – | 1.87% | 7 |
|
|
2017
Q1 | $1.44M | Buy |
22,108
+6,331
| +40% | +$398K | 1.7% | 15 |
|
|
2016
Q4 | $988K | Sell |
15,777
-65
| -0.4% | -$3.97K | 1.59% | 19 |
|
|
2016
Q3 | $999K | Buy |
15,842
+725
| +5% | +$46.9K | 1.68% | 11 |
|
|
2016
Q2 | $936K | Hold |
15,117
| – | – | 1.63% | 20 |
|
|
2016
Q1 | $863K | Sell |
15,117
-102
| -0.7% | -$5.68K | 0.65% | 55 |
|
|
2015
Q4 | $902K | Buy |
15,219
+490
| +3% | +$28.2K | 0.7% | 40 |
|
|
2015
Q3 | $801K | Hold |
14,729
| – | – | 0.65% | 50 |
|
|
2015
Q2 | $990K | Buy |
14,729
+880
| +6% | +$57.5K | 0.73% | 32 |
|
|
2015
Q1 | $811K | Buy |
13,849
+888
| +7% | +$53.6K | 0.61% | 52 |
|
|
2014
Q4 | $848K | Sell |
12,961
-3,536
| -21% | -$223K | 0.68% | 42 |
|
|
2014
Q3 | $953K | Hold |
16,497
| – | – | 0.79% | 31 |
|
|
2014
Q2 | $931K | Hold |
16,497
| – | – | 0.75% | 32 |
|
|
2014
Q1 | $848K | Hold |
16,497
| – | – | 0.71% | 32 |
|
|
2013
Q4 | $871K | Sell |
16,497
-73
| -0.4% | -$3.59K | 0.73% | 31 |
|
|
2013
Q3 | $741K | Hold |
16,570
| – | – | 0.68% | 39 |
|
|
2013
Q2 | $685K | Buy |
+16,570
| New | +$725K | 0.67% | 37 |
|
Other funds holding ABBV
Weaver C. Barksdale & Associates's ABBV Position: Q2 2026 in Review
Weaver C. Barksdale & Associates reduced its AbbVie (ABBV) stake by 0.11% in Q2 2026, selling an estimated $2.37K and leaving 9,898 shares worth $2.49M. The position accounts for 2.23% of the portfolio, ranked #5.
Weaver C. Barksdale & Associates first reported a position in ABBV in Q2 2013 and has held it in 38 quarters since. The position peaked at $2.92M in Q1 2022. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Weaver C. Barksdale & Associates held 9,898 shares of AbbVie worth $2.49M as of Q2 2026.
- Weaver C. Barksdale & Associates sold 11 AbbVie shares in Q2 2026, an estimated $2.37K.
- AbbVie made up 2.23% of Weaver C. Barksdale & Associates's portfolio in Q2 2026, its #5 holding.
- Weaver C. Barksdale & Associates first reported a position in AbbVie in Q2 2013 and has held it in 38 quarters since.
- Weaver C. Barksdale & Associates's AbbVie position peaked at $2.92M in Q1 2022.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Weaver C. Barksdale & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.